Pipeline
Dawah Pharmaceuticals Inc. is advancing global healthcare through a robust pipeline of essential drugs in collaboration with top-tier international Contract Manufacturing Organizations (CMOs). By leveraging strategic overseas partnerships, we ensure the efficient delivery of FDA-compliant drugs that address critical therapeutic needs across a wide range of disease states.
Sterile Injectables
-
Antipsychotics Help manage both chronic and acute mental health disorders to stabilize patients
-
​Paralytics Used to facilitate anesthesia and ensure patient immobilization during surgery or critical care
-
Antibiotics Target and treat severe bacterial infections, including resistant strains
-
Oncology Drugs Provide innovative and life-saving treatments for various types of cancer
-
Antifungals Treat systemic and invasive fungal infections effectively.
Ophthalmics
-
Anti-inflammatory Agents: Reducing inflammation in ocular diseases.
-
Antibiotic-Corticosteroid Combinations: Treating bacterial infections with concurrent inflammation.
-
Antihistamines: Providing relief from allergic conjunctivitis and related ocular allergies.
Bags and (TPN)
-
Pain Management: Offering intravenous acetaminophen for effective pain and fever control.
-
Critical Care Solutions: Including dopamine and electrolytes for emergency and intensive care applications.
-
Nutritional Support: High-use TPN formulations for patients with impaired oral intake.
Overseas Partnerships
-
Dawah Pharmaceuticals has meticulously evaluated over 30 global CMOs and strategically partnered with two industry leaders based overseas. These partnerships are integral to our operations
-
Optimize manufacturing costs with contributions of the sterile production cost by our selected CMOs.
Activities Provided by CMOs
-
Comprehensive Development: Formulation, process design, and analytical testing.
-
Regulatory Preparedness: Manufacturing registration batches and compiling FDA dossiers.
-
Stability Testing: Ensuring efficacy and safety over extended periods.
Our partnerships empower Dawah Pharmaceuticals to maintain agility while delivering high-quality, FDA-compliant drugs to address critical healthcare needs. By continuously assessing market trends and patient requirements, we are committed to expanding our pipeline and improving global access to essential medications.
Commitment to Excellence
Here is a list of the drugs we plan to bring to the U.S. market via JV, along with their indications and projected launch years.
2026–2027
Bacterial infections (oral antibiotic)
2028
Type 2 diabetes, weight management
2028–2029
Acute heart failure, cardiac stress testing
2028–2029
Edema, congestive heart failure, hypertension
2028–2029
Short-term pain relief (injectable NSAID)
2028–2029
Gallstone dissolution, primary biliary cholangitis
2027–2028
Antiplatelet (cardiovascular diseases)
2028–2029
Sedation in intensive care and surgical settings
2028–2029
Induction of general anesthesia
2028–2029
Short-term pain relief (injectable NSAID)
2028–2029
Alzheimer’s disease
2031
Chemotherapy, autoimmune diseases (oncology)